Downregulation of FOXK2 is Associated with Poor Prognosis in Patients with Gastric Cancer

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2018 Sep 18

PMID 30221666

Citations 13

Authors

Xi Liu

Xiaodong Wei

Wei Niu

Dong Wang

Bo Wang

Hao Zhuang

Affiliations

Soon will be listed here.

Abstract

Forkhead box (FOX)K2 (FOXK2) is a member of the FOX transcription factor family. It has been suggested previously that FOXK2 is required to suppress tumor growth; however, the exact role of FOXK2 in gastric cancer remains to be elucidated. In the present study, the association between FOXK2 expression and the clinicopathological characteristics of patients with gastric cancer was investigated. The prognostic value of FOXK2 expression and the significance of clinicopathological parameters in the overall survival (OS) and progression‑free survival of patients were also determined by survival analysis. To investigate the functional roles of FOXK2, it was downregulated in BGC‑823 cells using small interfering (si)RNA, and upregulated using a FOXK2 plasmid. Colony formation, Cell Counting Kit‑8 and cell proliferation analyses were conducted to examine the proliferation of gastric cancer cells. Transwell and wound‑healing assays were performed to investigate the effect of FOXK2 expression on gastric cancer cell migration and invasion. The clinical data demonstrated that FOXK2 expression was reduced in high‑grade gastric cancer tissues, and a low level of FOXK2 expression indicated a poor prognosis. The data obtained from the Human Protein Atlas revealed that patients with gastric cancer and a high level of FOXK2 expression had a longer OS time. The results of colony formation assays, Transwell and wound healing assays demonstrated that FOXK2 repressed the proliferation, invasion and migration of gastric cancer cells, respectively. The findings indicated that FOXK2 may serve as a promising therapeutic target in gastric cancer. Taken together, the findings of the present study demonstrated that FOXK2 functions as a tumor suppressor in gastric cancer; the loss of FOXK2 may induce the growth and invasion of gastric cancer cells.

Citing Articles

Foxk2 Enhances Adipogenic Differentiation by Relying on the Transcriptional Activation of Peroxisome Proliferator-Activated Receptor Gamma.

Zhang S, You Y, Li R, Li M, Li Y, Yuan H J Cell Mol Med. 2025; 29(1):e70332.

PMID: 39789420 PMC: 11717668. DOI: 10.1111/jcmm.70332.

Emerging roles of FOXK2 in cancers and metabolic disorders.

Xing X, Que X, Zheng S, Wang S, Song Q, Yao Y Front Oncol. 2024; 14:1376496.

PMID: 38741782 PMC: 11089157. DOI: 10.3389/fonc.2024.1376496.

O-GlcNAcylation of FOXK1 orchestrates the E2F pathway and promotes oncogenesis.

Masclef L, Ahmed O, Iannantuono N, Gagnon J, Gushul-Leclaire M, Boulay K bioRxiv. 2024; .

PMID: 38463952 PMC: 10925292. DOI: 10.1101/2024.03.01.582838.

Regulation and roles of FOXK2 in cancer.

Kang Y, Zhang K, Sun L, Zhang Y Front Oncol. 2022; 12:967625.

PMID: 36172141 PMC: 9510715. DOI: 10.3389/fonc.2022.967625.

The Function of FoxK Transcription Factors in Diseases.

Yu M, Yu H, Mu N, Wang Y, Ma H, Yu L Front Physiol. 2022; 13:928625.

PMID: 35903069 PMC: 9314541. DOI: 10.3389/fphys.2022.928625.

References

Guo J, Guo C, He Z, Cai X, Mou Y . High MMP-26 expression in glioma is correlated with poor clinical outcome of patients. Oncol Lett. 2018; 16(2):2237-2242. PMC: 6036463. DOI: 10.3892/ol.2018.8880. View

Ji C, Wang Y, Xiang D, Liu Q, Zhou Z, Qian F . Kir2.1 Interaction with Stk38 Promotes Invasion and Metastasis of Human Gastric Cancer by Enhancing MEKK2-MEK1/2-ERK1/2 Signaling. Cancer Res. 2018; 78(11):3041-3053. PMC: 8111788. DOI: 10.1158/0008-5472.CAN-17-3776. View

Roussos E, Keckesova Z, Haley J, Epstein D, Weinberg R, Condeelis J . AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 2010; 70(19):7360-4. DOI: 10.1158/0008-5472.CAN-10-1208. View

Chen S, Jiang S, Hu F, Xu Y, Wang T, Mei Q . Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes. Oncol Rep. 2017; 37(4):2335-2347. DOI: 10.3892/or.2017.5461. View

Min K, Kim D, Son B, Kim D, Kim E, Seo J . A High Ki67/BCL2 Index Could Predict Lower Disease-Free and Overall Survival in Intestinal-Type Gastric Cancer. Eur Surg Res. 2017; 58(3-4):158-168. DOI: 10.1159/000448945. View

Yamaguchi H, Du Y, Nakai K, Ding M, Chang S, Hsu J . EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene. 2017; 37(2):208-217. PMC: 5786281. DOI: 10.1038/onc.2017.311. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Dominguez C, David J, Palena C . Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol. 2017; 47:177-184. PMC: 5698091. DOI: 10.1016/j.semcancer.2017.08.002. View

10.

Sun Y, Xu K, He M, Fan G, Lu H . Overexpression of Glypican 5 (GPC5) Inhibits Prostate Cancer Cell Proliferation and Invasion via Suppressing Sp1-Mediated EMT and Activation of Wnt/β-Catenin Signaling. Oncol Res. 2017; 26(4):565-572. PMC: 7844840. DOI: 10.3727/096504017X15044461944385. View

11.

Maounis N, Draberova E, Trakas N, Chorti M, Riga D, Tzannis K . Expression of γ-tubulin in non-small cell lung cancer and effect on patient survival. Histol Histopathol. 2018; 34(1):81-90. DOI: 10.14670/HH-18-027. View

12.

Nestal de Moraes G, Ji Z, Fan L, Yao S, Zona S, Sharrocks A . SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells. Oncogenesis. 2018; 7(3):29. PMC: 5852961. DOI: 10.1038/s41389-018-0038-6. View

13.

Nestal de Moraes G, Khongkow P, Gong C, Yao S, Gomes A, Ji Z . Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer. Oncogenesis. 2015; 4:e167. PMC: 4767938. DOI: 10.1038/oncsis.2015.26. View

14.

Apicella M, Corso S, Giordano S . Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017; 8(34):57654-57669. PMC: 5593674. DOI: 10.18632/oncotarget.14825. View

15.

Shi Z, Qian X, Li L, Zhang J, Zhu S, Zhu J . Nuclear translocation of β-catenin is essential for glioma cell survival. J Neuroimmune Pharmacol. 2012; 7(4):892-903. DOI: 10.1007/s11481-012-9354-3. View

16.

Skrypek N, Goossens S, De Smedt E, Vandamme N, Berx G . Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity. Trends Genet. 2017; 33(12):943-959. DOI: 10.1016/j.tig.2017.08.004. View

17.

Marais A, Ji Z, Child E, Krause E, Mann D, Sharrocks A . Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK·cyclin complexes. J Biol Chem. 2010; 285(46):35728-39. PMC: 2975197. DOI: 10.1074/jbc.M110.154005. View

18.

Shi Z, Liu J, Yu X, Huang J, Shen S, Zhang Y . Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients. Ann Surg Oncol. 2015; 23(1):211-7. DOI: 10.1245/s10434-015-4515-2. View

19.

Aoyama T, Yoshikawa T, Fujikawa H, Hayashi T, Ogata T, Cho H . Prognostic factors in stage IB gastric cancer. World J Gastroenterol. 2014; 20(21):6580-5. PMC: 4047344. DOI: 10.3748/wjg.v20.i21.6580. View

20.

Yuan J, Zeng J, Shuai C, Liu Y . TWSG1 Is a Novel Tumor Suppressor in Gastric Cancer. DNA Cell Biol. 2018; 37(6):574-583. DOI: 10.1089/dna.2018.4188. View